QALY - DEEP DIVE INTO THE ECONOMIC MODELS

21. Jun 2021

2 days course

English

13,000 DKK ex VAT
(app. 1,748 EUR ex VAT)
50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Do you work with Market Access in Denmark, Norway or Sweden? Are you up to date with the common issues and pitfalls seen in economic models submitted to a Health Technology Assessment Agency (HTA) - especially pertaining to those most commonly used in connection with the QALY method?

Following on from the course ”Understand the QALY method - just as well as the Danish Medicines Council”, this course is a deeper dive into some of the issues encountered in economic modelling for national HTA.

The course also covers how the results of economic models can be conveyed to non-experts, and introduces some common pricing negotiation strategies that are used by international HTA agencies.

The course is conducted in collaboration with leading Health Economists from York Health Economic Consortium – wholly owned by University of York (UK), a world leading institution within the field of health economics.

 

Key words

  • Model critique
  • Market Access
  • HTA
  • QALY
  • Danish Medicines Council
  • Health economic models
  • Interpreting model results
  • Pricing strategies
  • The Nordics
Read more

Course leader(s) & Lecturers

  • Hayden Holmes
    Course leader
    Project Director
    York Health Economics Consortium
  • Hannah Baker
    Lecturer
    Research Consultant
    York Health Economics Consortium
  • Matthew Taylor
    Lecturer
    Director
    York Health Economics Consortium
  • Will Green
    Lecturer
    Project Director
    York Health Economics Consortium
  • Sara Graziadio
    Lecturer
    Project Director
    York Health Economics Consortium
See all

IS THIS COURSE FOR YOU?

  • Market Access specialists
  • HEOR specialists
  • Medical Advisors
  • Health Economists

What you will learn

  1. How to critique complex economic models
  2. Common issues/pitfalls seen in economic models submitted to HTA
  3. How to communicate model results to non-experts
  4. An overview of common pharmaceutical pricing strategies

What your company will get

  1. An employee who understands the complexities of economic models in the context of the QALY framework
  2. An employee who understands how the national HTA agencies will critique model submissions
  3. An employee who understands how to communicate results of economic models to non-experts
  4. An employee who understands different pricing strategies that are available to decision makers

Course calendar

Starting 21. Jun 2021
21. Jun 2021 9:30-16:00

DAY 1

Critiquing models

  • Critiquing survival models
  • Critiquing patient level simulation models
  • Critiquing regression-based models: Interpreting stochastic outputs

Common issues in models submitted to HTA & Network meta-analyses

  • How to extrapolate data
  • How to model treatment effect waning
  • How to accurately capture background costs
  • Consideration of treatments that are not cost-effective at zero prices
  • Health related quality of life (HRQoL) elicitation
  • Network meta-analysis
  1. How to undertake a feasibility assessment for an NMA
  2. Critiquing NMAs
22. Jun 2021 9:30-16:00

DAY 2

Communicating model results to non-experts & case studies from NICE

  • What is the best practice for reporting standards?
  • How do we best communicate model outputs to non-technical people in HTA agencies?
  • Two case studies from NICE submissions covering:
  1. An overview of the evidence and decision making
  2. Clinical inputs
  3. Bias
  4. Uncertainty
  5. Model assumptions that were crucial in the assessment
  6. Interpret the results of the analysis and uncertainty around this

Pricing negotiation strategies • Why is pricing important? 

  • Is there a trade-off between early access and clinical evidence?
  • Common pricing strategies used by international HTA agencies including:
  1. Coverage with evidence development
  2. Risk sharing agreements
  3. Value based pricing
  4. Rebates
  5. Commercial proposals for products nearing patent expiry
  6. Multiproduct bundling
  • The presentation will include an Excel demonstration on selected pricing strategies
  • Q & A – panel discussion with all presenters
Practical information

Registration

Registration deadline
6. Jun 2021
Online format

Registration deadline expired
Sometimes things change. This is the expected programme.

Course information

Literature

Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course. The mandatory readings are also part of the examination syllabus.

Prerequisites

To benefit from this course, it is an advantage to have participated in the course ”Understand the QALY method - just as well as the Danish Medicines Council”.

If you have not participated in this course, a solid background in health economics is necessary.

Examination

There is no examination for this course.

Course leader(s)

Hayden Holmes
Project Director
York Health Economics Consortium

Lecturers

Hayden Holmes
Project Director
York Health Economics Consortium
Hannah Baker
Research Consultant
York Health Economics Consortium
Matthew Taylor
Director
York Health Economics Consortium
Will Green
Project Director
York Health Economics Consortium
Sara Graziadio
Project Director
York Health Economics Consortium

You may also be interested in these courses

Want to know more or need help?

Contact Educational Programme Leader Maibritt Thoft-Christensen at +45 39 15 09 32

Send me a message